Product Program year 2023 Source: CMS Open Payments

Duavee

Drug Genitourinary (Sexual Health);Womens Health

NDC 0008-1123-12

Open in the dashboard

General payments

$101,024

3,882 payments

Research payments

$0

0 payments

Through program year 2023, $101,024 in general payments and $0 in research payments were reported against Duavee (Genitourinary (Sexual Health);Womens Health).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

5 rows
Year Kind Amount Payments
2023 General $92,896 3,729
2022 General $802 14
2021 General $204 10
2020 General $704 41
2019 General $6,418 88

Breakdown

Who paid General payments · program years 2019–2023
  1. Pfizer Inc. $100,399 3,877 payments
  2. Pfizer International LLC $538 2 payments
  3. PBG Puerto Rico LLC $86 3 payments
Top recipients General payments · program year 2023
  1. Risa Kagan Obstetrics & Gynecology · Berkeley, CA $9,898 11% · 10 payments
  2. Gloria Richard-Davis Reproductive Endocrinology · Little Rock, AR $8,396 9% · 2 payments
  3. Mary Minkin Obstetrics & Gynecology · New Haven, CT $1,720 2% · 4 payments
  4. Steven Goldstein Obstetrics & Gynecology · New York, NY $1,718 2% · 6 payments
  5. Jessica Shepherd Gynecology · Dallas, TX $942 1% · 2 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2023.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2023
  1. Obstetrics & Gynecology $36,628 40% · 1,011 practitioners
  2. Nurse Practitioner, Family Nurse Practitioner $12,519 14% · 526 practitioners
  3. Family Medicine $9,896 11% · 419 practitioners
  4. Reproductive Endocrinology Obstetrics & Gynecology $8,538 9% · 4 practitioners
  5. Internal Medicine $4,749 5% · 210 practitioners

The top 5 of 49 specialties; each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2023
  1. California $14,057 15% · 162 recipients
  2. Texas $10,981 12% · 476 recipients
  3. Florida $9,907 11% · 403 recipients
  4. Arkansas $9,771 11% · 56 recipients
  5. New York $4,860 5% · 114 recipients

The top 5 of 47 states; each share is of general payments naming this product in 2023 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

1,256

Prescriptions dispensed, refills included

Drug cost

$368,069

Paid at the pharmacy, in all

Prescribers

50

With 11 or more claims of it

Medicare Part D drugs matched to DUAVEE, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Duavee Estrogens,conj/Bazedoxifene Same name 50 1,256 $368,069

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 50 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Caroline Peterson Obstetrics & Gynecology OH 146 $41,633 None on record
Howard Mandel Obstetrics & Gynecology CA 110 $27,388 $29
Jannet Huang Internal Medicine CA 108 $49,801 None on record
John Lee Obstetrics & Gynecology FL 64 $16,635 None on record
John Link Hematology-Oncology CA 56 $13,570 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 50 with Patron
3,882 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record